Physician profile
Robert Hiltz
NPI 1679549331
$164,561.78
in general payments reported to CMS, 2019-2025
23 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $22K · 2021: $18K · 2022: $39K · 2023: $38K · 2024: $14K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Food and Beverage: $8,008 · Travel and Lodging: $2,564 · Education: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,087.50 |
| Food and Beverage | $8,008.05 |
| Travel and Lodging | $2,563.61 |
| Education | $319.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $89,286.48 | 2019-2025 | |
| Lilly USA, LLC | $69,295.53 | 2019-2024 | Taltz |
| Amgen INC. | $2,556.44 | 2019-2025 | Enbrel, Otezla, Enbrel |
| Ucb, INC. | $944.51 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $395.40 | 2019-2023 | |
| Genentech USA, INC. | $305.80 | 2019-2021 | |
| Janssen Biotech, INC. | $304.61 | 2019-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $286.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $177.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $166.20 | 2024-2025 | Acthar |
| Horizon Therapeutics Plc | $141.65 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $138.38 | 2019-2020 | |
| Celgene Corporation | $124.83 | 2019 | |
| Genentech, INC. | $117.90 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $65.27 | 2024-2025 | Teriparatide |
| Hikma Pharmaceuticals USA | $42.24 | 2019-2021 | |
| Radius Health, INC. | $34.17 | 2020-2025 | Tymlos |
| Glaxosmithkline, LLC. | $18.05 | 2023 | Benlysta |
| Scilex Pharmaceuticals INC. | $17.38 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.71 | 2020 | |
| Novo Nordisk INC | $14.68 | 2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $14.07 | 2025 | Saphnelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hiltz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.